ProShare Advisors
PSTX

ProShare Advisors’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

ProShare Advisors’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-19,334
Closed -$186K – 2289
2024
Q4 		$186K Buy
19,334
+6,362
+49% +$33.2K ﹤0.01% 1906
2024
Q3 		$37.1K Buy
+12,972
New +$40.2K ﹤0.01% 2009
2024
Q2 		– Sell
-12,210
Closed -$39K – 2029
2024
Q1 		$39K Buy
12,210
+960
+9% +$3.2K ﹤0.01% 1935
2023
Q4 		$37.8K Sell
11,250
-3,262
-22% -$8.4K ﹤0.01% 1885
2023
Q3 		$34.5K Buy
14,512
+58
+0.4% +$122 ﹤0.01% 1750
2023
Q2 		$25.4K Buy
+14,454
New +$36.9K ﹤0.01% 1825
2022
Q2 		– Sell
-11,861
Closed -$53K – 2182
2022
Q1 		$53K Sell
11,861
-3,223
-21% -$14.5K ﹤0.01% 2111
2021
Q4 		$103K Sell
15,084
-1,918
-11% -$13.1K ﹤0.01% 2201
2021
Q3 		$124K Sell
17,002
-1,628
-9% -$14K ﹤0.01% 1882
2021
Q2 		$187K Buy
18,630
+1,196
+7% +$10.7K ﹤0.01% 2163
2021
Q1 		$166K Buy
17,434
+4,918
+39% +$48.2K ﹤0.01% 2082
2020
Q4 		$137K Buy
+12,516
New +$132K ﹤0.01% 1940

Other funds holding PSTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ProShare Advisors's PSTX Position: Q1 2025 in Review

ProShare Advisors sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 19,334 shares — an estimated $186K sold.

ProShare Advisors first reported a position in PSTX in Q4 2020 and held it in 12 quarters. The position peaked at $187K in Q2 2021. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

  • ProShare Advisors reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • ProShare Advisors sold 19,334 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $186K.
  • ProShare Advisors first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2020 and held it in 12 quarters.
  • ProShare Advisors's Poseida Therapeutics, Inc. Common Stock position peaked at $187K in Q2 2021.
  • 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on ProShare Advisors's 13F filing for Q1 2025, filed 8 May 2025.